Compare AEHL & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEHL | ENSC |
|---|---|---|
| Founded | 1993 | 2003 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0M | 1.7M |
| IPO Year | 2009 | N/A |
| Metric | AEHL | ENSC |
|---|---|---|
| Price | $0.51 | $0.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 285.1K | 217.2K |
| Earning Date | 05-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $55.01 |
| Revenue Next Year | N/A | $1,033.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.31 |
| 52 Week High | $6.53 | $2.75 |
| Indicator | AEHL | ENSC |
|---|---|---|
| Relative Strength Index (RSI) | 30.20 | 39.10 |
| Support Level | $0.48 | $0.31 |
| Resistance Level | $1.46 | $0.63 |
| Average True Range (ATR) | 0.07 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 6.92 | 22.62 |
Antelope Enterprise Holdings Ltd operates in three reportable operating segments: Business Management Consulting, information system technology consulting services including the sales of software use rights for digital data deposit platforms and asset management systems, and online social media platform development and consulting; Natural Gas Power generation, which was in the initial development stage; and Live-Streaming e-commerce segment, providing a one-stop solution for customers to enable them to utilize the growing sales channel of livestreaming ecommerce. The business of the Company is engaged in the PRC and the United States.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.